These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31970776)

  • 1. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.
    Giugliano DN; Berger AC; Pucci MJ; Rosato EL; Evans NR; Meidl H; Lamb C; Levine D; Palazzo F
    J Gastrointest Surg; 2017 Sep; 21(9):1377-1384. PubMed ID: 28664255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Impact of Total Resected Lymph Nodes in Esophageal Cancer Patients With and Without Neoadjuvant Chemoradiation.
    Ho HJ; Chen HS; Hung WH; Hsu PK; Wu SC; Chen HC; Wang BY
    Ann Surg Oncol; 2018 Dec; 25(13):3820-3832. PubMed ID: 30284131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Log odds of positive lymph nodes predicts survival in patients treated with neoadjuvant therapy followed by esophagectomy.
    Ye G; Chen Z; Wang L; Hu Z; Bian Y; Yang X; Lu T; Zhan C; Lin Z; Wang Q
    J Surg Oncol; 2020 Jun; 121(7):1074-1083. PubMed ID: 32141098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
    Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
    Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent of lymph node removal during esophageal cancer surgery and survival.
    van der Schaaf M; Johar A; Wijnhoven B; Lagergren P; Lagergren J
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25748792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study.
    Semenkovich TR; Subramanian M; Yan Y; Hofstetter WL; Correa AM; Cassivi SD; Inra ML; Stiles BM; Altorki NK; Chang AC; Brescia AA; Darling GE; Allison F; Broderick SR; Etchill EW; Fernandez FG; Chihara RK; Litle VR; Muñoz-Largacha JA; Kozower BD; Puri V; Meyers BF
    Ann Thorac Surg; 2019 Sep; 108(3):828-836. PubMed ID: 31229485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage.
    Luna RA; Dolan JP; Diggs BS; Bronson NW; Sheppard BC; Schipper PH; Tieu BH; Feeney BT; Gatter KM; Vaccaro GM; Thomas CR; Hunter JG
    J Gastrointest Surg; 2015 Jul; 19(7):1201-7. PubMed ID: 25910454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of D2 Versus D1 Lymphadenectomy in Siewert II Gastroesophageal Junction (GEJ) Cancer.
    Alcasid NJ; Fink D; Banks KC; Susai CJ; Barnes K; Wile R; Sun A; Patel A; Ashiku S; Velotta JB
    Ann Surg Oncol; 2024 Nov; 31(12):8148-8156. PubMed ID: 39080133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery.
    Pei S; Huang JQ; Liang HW; Liu Y; Chen L; Yu BB; Huang W; Pan XB
    Dis Esophagus; 2024 Jul; 37(8):. PubMed ID: 38553783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival.
    Solomon D; Deeb AL; Tarabine K; Xie Y; Mazzola E; Zhao L; Hammer MM; Jaklitsch MT; Swanson SJ; Bueno R; Wee JO
    J Thorac Cardiovasc Surg; 2024 Jul; 168(1):278-289.e4. PubMed ID: 37967764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Jiang D; Liu XB; Xing WQ; Chen PN; Feng SK; Yan S; Lerut T; Sun HB
    Dis Esophagus; 2023 Apr; 36(5):. PubMed ID: 36385581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.